HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Martin Zehetmayer Selected Research

Particle Accelerators

2/2021Hypofractionated stereotactic photon radiotherapy of choroidal melanoma: 20-year experience.
6/2018Early ultrasonographic tumor regression after linear accelerator stereotactic fractionated photon radiotherapy of choroidal melanoma as a predictor for metastatic spread.
8/2013Hypofractionated stereotactic photon radiotherapy of posteriorly located choroidal melanoma with five fractions at ten Gy--clinical results after six years of experience.
9/2011Local tumor control, visual acuity, and survival after hypofractionated stereotactic photon radiotherapy of choroidal melanoma in 212 patients treated between 1997 and 2007.
9/2003Tumour regression of uveal melanoma after ruthenium-106 brachytherapy or stereotactic radiotherapy with gamma knife or linear accelerator.
7/2003A noninvasive eye fixation and computer-aided eye monitoring system for linear accelerator-based stereotactic radiotherapy of uveal melanoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Martin Zehetmayer Research Topics

Disease

11Melanoma (Melanoma, Malignant)
02/2021 - 08/2003
7Neoplasms (Cancer)
02/2021 - 05/2003
7Uveal melanoma
07/2012 - 03/2003
4Cataract (Cataracts)
07/2012 - 08/2003
3Neovascular Glaucoma
05/2012 - 12/2007
1Neoplasm Metastasis (Metastasis)
06/2018
1Inflammation (Inflammations)
07/2012
1Carcinogenesis
07/2012
1Optic Nerve Diseases (Optic Neuropathy)
05/2012
1Retinal Detachment (Retinal Detachments)
12/2007
1Melanosis (Freckles)
08/2003
1AIDS-Related Complex (ARC)
03/2003
1Corneal Injuries
01/2002
1Vision Disorders (Hemeralopia)
01/2002
1Wounds and Injuries (Trauma)
01/2002

Drug/Important Bio-Agent (IBA)

4Ruthenium-106IBA
02/2021 - 09/2003
2Fluorescein (Funduscein)FDA LinkGeneric
08/2013 - 09/2011
1Dihydrotachysterol (AT 10)IBA
08/2013
1InterferonsIBA
07/2012
1InterleukinsIBA
07/2012
1Platelet-Derived Growth FactorIBA
07/2012
1Proteins (Proteins, Gene)FDA Link
07/2012
1SuspensionsIBA
07/2012
1flt3 ligand protein (flt3 ligand)IBA
07/2012
1Interleukin-6 (Interleukin 6)IBA
07/2012
1Interleukin-7 (Interleukin 7)IBA
07/2012
1CytokinesIBA
07/2012
1Interleukin-8 (Interleukin 8)IBA
07/2012
1ChemokinesIBA
07/2012
1Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA
07/2012
1Chemokine CCL5IBA
07/2012
1Macrophage Inflammatory Proteins (Macrophage Inflammatory Protein 1)IBA
07/2012
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
07/2012
1Protons (Proton)IBA
05/2012
1AS 35IBA
01/2012
1Ranibizumab (Lucentis)FDA Link
12/2007
1Mitomycin (Mitomycin-C)FDA LinkGeneric
08/2003
1Retinaldehyde (Retinal)IBA
01/2002

Therapy/Procedure

12Radiotherapy
02/2021 - 03/2003
6Particle Accelerators
02/2021 - 07/2003
6Brachytherapy
02/2021 - 07/2003
3Therapeutics
02/2004 - 03/2003
2Aftercare (After-Treatment)
06/2018 - 01/2012
1Traction
07/2012
1Lasers (Laser)
06/2008
1Drug Therapy (Chemotherapy)
08/2003
1Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated)
03/2003